Scorpius Holdings, Inc. (SCPX)
USD 0.29
(-0.87%)
USD 0.29
(-0.87%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -2.21 Million USD | -427.69% |
| 2022 | -420.02 Thousand USD | -129.55% |
| 2021 | 1.42 Million USD | -51.79% |
| 2020 | 2.94 Million USD | -3.32% |
| 2019 | 3.04 Million USD | -47.37% |
| 2018 | 5.79 Million USD | 281.19% |
| 2017 | 1.51 Million USD | 344.89% |
| 2016 | 341.64 Thousand USD | 394.52% |
| 2015 | -116 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 769.36 Thousand USD | -58.32% |
| 2024 Q2 | -1.9 Million USD | -347.93% |
| 2023 Q2 | 274.08 Thousand USD | 77.79% |
| 2023 Q3 | 178.1 Thousand USD | -35.02% |
| 2023 FY | -2.21 Million USD | -427.69% |
| 2023 Q1 | 154.16 Thousand USD | 111.32% |
| 2023 Q4 | 1.84 Million USD | 936.38% |
| 2022 Q2 | -487.01 Thousand USD | -2901.8% |
| 2022 FY | -420.02 Thousand USD | -129.55% |
| 2022 Q4 | -1.36 Million USD | -25.81% |
| 2022 Q3 | -1.08 Million USD | -122.23% |
| 2022 Q1 | -16.22 Thousand USD | -104.05% |
| 2021 Q1 | 538.64 Thousand USD | 0.0% |
| 2021 FY | 1.42 Million USD | -51.79% |
| 2021 Q4 | 400.69 Thousand USD | -20.11% |
| 2021 Q3 | 501.56 Thousand USD | 9.16% |
| 2021 Q2 | 459.49 Thousand USD | -14.69% |
| 2020 FY | 2.94 Million USD | -3.32% |
| 2019 FY | 3.04 Million USD | -47.37% |
| 2018 FY | 5.79 Million USD | 281.19% |
| 2017 FY | 1.51 Million USD | 344.89% |
| 2016 FY | 341.64 Thousand USD | 394.52% |
| 2015 FY | -116 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 160 Thousand USD | 1485.26% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -786.566% |
| Armata Pharmaceuticals, Inc. | -29.24 Million USD | 92.42% |
| Actinium Pharmaceuticals, Inc. | -709 Thousand USD | -212.612% |
| Azitra, Inc. | 260.45 Thousand USD | 950.992% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | 398.306% |
| Chromocell Therapeutics Corporation | -2.57 Million USD | 14.073% |
| Calidi Biotherapeutics, Inc. | -1.25 Million USD | -76.466% |
| CEL-SCI Corporation | -3.95 Million USD | 44.006% |
| iBio, Inc. | -1.02 Million USD | -116.236% |
| Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 126.788% |
| MAIA Biotechnology, Inc. | - USD | Infinity% |
| Matinas BioPharma Holdings, Inc. | -13.39 Million USD | 83.451% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -1757.929% |
| NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | 128.074% |
| NanoViricides, Inc. | -759.01 Thousand USD | -192.013% |
| Oragenics, Inc. | -15.45 Million USD | 85.657% |
| BiomX Inc. | -1.22 Million USD | -80.49% |
| BiomX Inc. | -1.22 Million USD | -80.49% |
| Protalix BioTherapeutics, Inc. | 42.51 Million USD | 105.214% |
| Palatin Technologies, Inc. | 4.39 Million USD | 150.46% |